# | Title | Journal | Year | Citations |
---|
1 | Screening and Prostate-Cancer Mortality in a Randomized European Study | New England Journal of Medicine | 2009 | 3,540 |
2 | Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up | Lancet, The | 2014 | 1,261 |
3 | Prostate-Cancer Mortality at 11 Years of Follow-up | New England Journal of Medicine | 2012 | 1,105 |
4 | Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation | PLoS Biology | 2012 | 1,064 |
5 | Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) | Lancet, The | 2012 | 759 |
6 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci | Nature Genetics | 2018 | 652 |
7 | Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy | European Urology | 2017 | 638 |
8 | Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer | European Urology | 2014 | 601 |
9 | Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators | European Urology | 2018 | 590 |
10 | Magnetic Resonance Imaging–targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysis | European Urology | 2015 | 569 |
11 | Active Surveillance for Prostate Cancer: A Systematic Review of the Literature | European Urology | 2012 | 518 |
12 | Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study | European Urology | 2013 | 450 |
13 | EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin | European Urology | 2016 | 445 |
14 | EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction | European Urology | 2009 | 429 |
15 | A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range | Journal of Urology | 2011 | 408 |
16 | Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology | European Urology | 2016 | 406 |
17 | Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial | European Urology | 2019 | 375 |
18 | The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation | European Urology | 2011 | 351 |
19 | The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review | European Urology | 2017 | 348 |
20 | Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder | European Urology | 2010 | 347 |
21 | ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice | European Urology | 2009 | 332 |
22 | Widespread and Functional RNA Circularization in Localized Prostate Cancer | Cell | 2019 | 317 |
23 | Androgens and male fertility | World Journal of Urology | 2003 | 305 |
24 | A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment | European Urology | 2016 | 290 |
25 | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2010 | 279 |
26 | Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort | European Urology | 2012 | 277 |
27 | Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram | Journal of Urology | 2007 | 271 |
28 | Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial | European Urology | 2012 | 269 |
29 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction | Nature Genetics | 2021 | 264 |
30 | Exosomes as Biomarker Treasure Chests for Prostate Cancer | European Urology | 2011 | 246 |
31 | The Potential of MicroRNAs as Prostate Cancer Biomarkers | European Urology | 2016 | 243 |
32 | Male infertility in cancer patients: Review of the literature | International Journal of Urology | 2010 | 242 |
33 | Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer | Oncogene | 2012 | 239 |
34 | Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer | Modern Pathology | 2015 | 239 |
35 | European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era | European Urology | 2020 | 239 |
36 | Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer | The Cochrane Library | 2019 | 234 |
37 | The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer | Journal of Urology | 2015 | 228 |
38 | Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection | European Urology | 2010 | 223 |
39 | Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells | European Urology | 2015 | 223 |
40 | Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches | Bioengineering | 2019 | 219 |
41 | Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) | European Urology | 2012 | 216 |
42 | The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients | European Urology | 2017 | 213 |
43 | Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer | European Urology | 2012 | 206 |
44 | The Mutational Landscape of Prostate Cancer | European Urology | 2013 | 203 |
45 | Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis | European Urology | 2019 | 203 |
46 | Anxiety and distress during active surveillance for early prostate cancer | Cancer | 2009 | 193 |
47 | Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer | European Urology | 2015 | 190 |
48 | Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer | European Journal of Cancer | 2013 | 183 |
49 | Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles | Journal of Extracellular Vesicles | 2021 | 182 |
50 | Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) | European Urology | 2009 | 180 |